October 19, 2016 News by Patricia Silva, PhD Apitope Regains Full Rights to Potential MS Therapy, ATX-MS-1467 ApitopeĀ andĀ Merck KGaAĀ announced that they have entered into an exclusive agreement regardingĀ ATX-MS-1467, a potential disease-modifying therapy for Ā multiple sclerosis (MS). Under itsĀ terms, Apitope will regain full global rights over ATX-MS-1467, as well as allĀ clinical data related to the compound. In 2009, the companyĀ grantedĀ exclusive global rights toĀ Merck KGaA to develop…
September 22, 2016 News by Charles Moore Information on Clinical Trials to Be More Complete and Accessible Under New HHS Rules The U.S. Department of Health and Human Services (HHS) recentlyĀ announced policy changes designed to make information about clinical trials of investigational drugs, biologics and products more widelyĀ available to the public, issuing amended rulesĀ that specify the requirements for registering clinical trials and for submitting summary results to itsĀ ClinicalTrials.govĀ website. The…
July 13, 2016 Columns by Laura Kolaczkowski Patient Recruitment for Clinical Trials: Something To Chew On This chewing gum handout in the exhibit area of the recent Drug Information Association (DIA) 2016 meeting says it all from the pharmaceutical company perspective – recruiting patients for their studies is often a distasteful and difficult process. While I appreciated the gum in this package, this image left a…
July 11, 2016 Columns by Laura Kolaczkowski Patient Engagement in Drug Development: DIA 2016 When I see a new drug for MS come to market, I only think of the company behind that product ā it could be one of the big names such as Genentech, Genzyme, EMD Serono, Biogen, or one of the many other players in the field.Ā I never stopped to…
June 13, 2016 News by Patricia Silva, PhD Genmab to Begin Phase 3 Trials of Ofatumumab to Treat Relapsing Multiple Sclerosis GenmabĀ announced plans to soon begin a Phase 3Ā clinical trial program assessing the subcutaneous formulation of ofatumumabĀ as a potential treatment forĀ relapsing multiple sclerosis (MS). The company, workingĀ in collaboration with its partnerĀ Novartis, will begin enrolling patients in September in trials that willĀ evaluate the efficacy and safety of ofatumumab compared…
June 10, 2016 News by InĆŖs Martins, PhD Multiple Sclerosis Treatment Targeting Immune Cells Begins Phase 1 Trial Arrien PharmaceuticalsĀ has initiated Phase 1 clinical trials of their first agent, ARN-6039, a molecule that targets a specific subset of immune cells called T helper 17 (Th17), for the potential treatment of patients with relapsing, remitting, and progressive multiple sclerosis (MS). A growing body of evidence has suggested a…
May 16, 2016 News by Patricia Silva, PhD #CMSC16 – Dr. Ellen Mowry, in Interview, Talks of Clinical Studies into Vitamin D and MS With an interestĀ multiple sclerosisĀ (MS) beforeĀ even startingĀ college, Dr. Ellen Mowry has spent her entire research career investigatingĀ the disease. Her epidemiological studies led her to indications that vitamin D might be particularly important for peopleĀ with MS, and she now dedicates her research to the topic ā knowledge she will share at the…
April 14, 2016 News by Patricia Silva, PhD Genentech to Present New Data from Phase 3 Trials of Ocrevus in MS Patients at AAN Annual Meeting GenentechĀ announced that it will present new data from three Phase 3 clinical trials ofĀ its experimental multiple sclerosis (MS) therapyĀ Ocrevus (ocrelizumab) at the 68th annual meeting of the American Academy of Neurology (AAN) being held in Vancouver, Canada, from April 15ā21, 2016. Additionally, results of a new endpoint for…
October 8, 2015 News by Patricia Inacio, PhD ECTRIMS Highlights Latest Developments in Multiple Sclerosis Research The 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) is currently being held in Barcelona, from 7 to 10 of October, 2015. As the biggest scientific event focused on Multiple Sclerosis, researchers and clinicians from around the world, with more than 8,000 participants, gather…
May 8, 2015 News by Patricia Silva, PhD MediciNova Completes Enrollment for Phase 2b Study of Experimental Progressive Multiple Sclerosis Treatment MediciNova, Inc., a publicly-traded biopharmaceutical company developing novel, small-molecule therapeutics for the treatment of diseases with unmet medical needs, recently announced that the National Institute of Neurological Disorders and Stroke (NINDS) notified the company of full enrollment of theirĀ ongoing clinical study evaluating ibudilastĀ (MN-166) for the treatment of progressive…